TY - JOUR
T1 - High-dose-intensity combination chemotherapy for advanced sarcomas
T2 - A pilot study
AU - Pronzato, Paolo
AU - Losardo, Pierluigi
AU - Pensa, Floriana
AU - Tognoni, Alessandra
PY - 1998
Y1 - 1998
N2 - A new polychemotherapy schedule involving high dose intensity and shortened intervals has been developed patients with advanced sarcomas. Mesna at 2500 mg/m
2 for 3 days, epidoxorubicin at 60 mg/m
2 on day 1, ifosfamide at 2500 mg/m
2 for 3 days, and dacarbazine at 450 mg/m
2 for 2 days were given every 2 weeks to a consecutive series of 20 patients. All patients received granulocyte colony-stimulating factor (CG-CSF; Filgrastim) subcutaneously at 300 μg from day 5 to day 12 of each cycle. The treatment was feasible and toxicity was acceptable, with grade IV myelotoxicity being observed only in one case. In all, 6 of 14 evaluable patients had an objective response; the median survival was 12 months. Toxicity was milder than that observed for the classic combination MAID, and the planned dose intensity was maintained in the majority of cases.
AB - A new polychemotherapy schedule involving high dose intensity and shortened intervals has been developed patients with advanced sarcomas. Mesna at 2500 mg/m
2 for 3 days, epidoxorubicin at 60 mg/m
2 on day 1, ifosfamide at 2500 mg/m
2 for 3 days, and dacarbazine at 450 mg/m
2 for 2 days were given every 2 weeks to a consecutive series of 20 patients. All patients received granulocyte colony-stimulating factor (CG-CSF; Filgrastim) subcutaneously at 300 μg from day 5 to day 12 of each cycle. The treatment was feasible and toxicity was acceptable, with grade IV myelotoxicity being observed only in one case. In all, 6 of 14 evaluable patients had an objective response; the median survival was 12 months. Toxicity was milder than that observed for the classic combination MAID, and the planned dose intensity was maintained in the majority of cases.
KW - Chemotherapy dose intensity
KW - G-CSF
KW - Sarcomas
UR - http://www.scopus.com/inward/record.url?scp=0031937658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031937658&partnerID=8YFLogxK
U2 - 10.1007/s002800050775
DO - 10.1007/s002800050775
M3 - Article
C2 - 9554597
AN - SCOPUS:0031937658
VL - 41
SP - 513
EP - 516
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 6
ER -